Metoprolol Tartrate Generics Uk (Metoprolol Tartrate)

Metoprolol Tartrate is a selective β1‑blocker used in cardiovascular disease management.

• Hypertension: lowers blood pressure by reducing heart rate and cardiac output.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Post‑myocardial infarction: improves survival by limiting cardiac workload.
• Heart failure: enhances ventricular function and reduces symptoms.
• Cardiac arrhythmias: controls heart rate and stabilises rhythm.

• Metoprolol Tartrate selectively antagonises β1‑adrenergic receptors located primarily in cardiac tissue. By blocking the action of endogenous catecholamines such as norepinephrine, it reduces intracellular cyclic AMP levels, leading to decreased calcium influx, slower sino‑atrial node firing, reduced myocardial contractility, and lower heart rate. The overall effect is diminished cardiac output and arterial pressure, contributing to its antihypertensive and anti‑ischemic properties.

Metoprolol Tartrate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed sensation, especially on standing.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea or abdominal discomfort.
• Headache: mild to moderate pain in the head.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Heart block: impaired electrical conduction in the heart.
• Bronchospasm: narrowing of airways, particularly in patients with asthma.
• Hypotension: significant drop in blood pressure causing faintness.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Depression: mood changes or depressive symptoms.

Before initiating Metoprolol Tartrate, several safety considerations should be reviewed.

• Cardiovascular assessment: evaluate heart rate, blood pressure and conduction abnormalities.
• Respiratory conditions: use cautiously in asthma or chronic obstructive pulmonary disease.
• Diabetes management: monitor blood glucose as beta‑blockade may mask hypoglycaemia signs.
• Hepatic or renal impairment: dose adjustments may be required in reduced organ function.
• Discontinuation: taper gradually to avoid rebound hypertension or tachycardia.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Store below 25°C: keep in the original pack, protect from moisture.

Metoprolol Tartrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Verapamil or diltiazem: combined use may cause excessive bradycardia or heart block.
• Clonidine withdrawal: abrupt cessation while on metoprolol can precipitate severe hypertension.
• Non‑selective beta‑blockers: concurrent use increases risk of cardiovascular depression.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive effect; monitor blood pressure.
• NSAIDs: can reduce antihypertensive response; check renal function.
• Antidepressants (e.g., SSRIs): may increase plasma metoprolol levels.
• Antidiabetic agents: beta‑blockade may mask hypoglycaemia; adjust monitoring.
• Calcium channel blockers: additive effects on heart rate; observe for bradycardia.